… primary report6; only the desvenlafaxine and placebo data from these trials … patient data
from an all-inclusive set of nine short-term, placebo-controlled trials confirm that desvenlafaxine …

… was 60% for desvenlafaxine 50 mg/d and 42% for placebo (P = … desvenlafaxine-treated
patients and 32% of placebo patients … of patients treated with desvenlafaxine 50 mg/d and 25% of …

… assess the efficacy, safety, and tolerability of desvenlafaxine (administered as desvenlafaxine
… A multicenter, randomized, double-blind, placebo-controlled trial was conducted in Europe …

… Objective: This study evaluated the efficacy and safety of desvenlafaxine succinate …
desvenlafaxine 100 mg/day (N = 114), 200 mg/day (N = 116), or 400 mg/day (N = 113) or placebo …

… The most common adverse events (incidence ≥10% in either desvenlafaxine group and
twice the rate of placebo) were dry mouth, constipation, insomnia, decreased appetite, …

… demonstrated in patient subgroups… desvenlafaxine 50 to 400 mg/d versus placebo in patients
in different age groups, 37 with desvenlafaxine 50 and 100 mg/d versus placebo in patients …

… Improvement with desvenlafaxine 50 mg/d compared with placebo in … patients with a
substantial placebo response during the screening period, there was a notable response to placebo …

… study evaluated the efficacy and tolerability of desvenlafaxine succinate (desvenlafaxine) in
the … Method: In this 8-week, multicenter, randomized, double-blind, placebo-controlled trial, …

… was to assess the efficacy of desvenlafaxine (administered as desvenlafaxine succinate) for
reducing impairment in functioning and well-being associated with MDD. Desvenlafaxine, a …

… This study assessed the efficacy of desvenlafaxine 50 mg/day compared with placebo for …
Data were pooled from six double-blind, placebo-controlled, desvenlafaxine 50 mg/day fixed-…